Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology April 9, 2025 Ellen R Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold et al. 23 citations
In an open-label pilot trial, 12 people with mild to moderate Parkinson's disease plus depression or anxiety received psilocybin (10 mg then 25 mg) with psychotherapy. No serious adverse events occurred, and no worsening of Parkinson's symptoms was observed. Non-motor and motor symptoms improved, and gains in some cognitive domains were sustained one month later. Depression and anxiety scores improved to a clinically meaningful degree and remained improved three months after dosing. These first results in any neurodegenerative disease suggest psilocybin therapy for Parkinson's disease warrants further study.